{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-100801","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2025-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.253540+00:00","generated_at":"2026-05-17T03:18:36.739279+00:00","sec_items":["1.01","1.02","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alto Neuroscience raises $50M in PIPE; accelerates ALTO-207 in TRD after FDA meeting","bullets":["Gross proceeds of ~$50M from PIPE led by Perceptive Advisors; priced at $5.914/share plus pre-funded warrants at $5.9139.","Proceeds to accelerate ALTO-207 development in treatment-resistant depression; Phase 2b potentially pivotal by mid-2026, Phase 3 by early 2027.","Successful FDA meeting for ALTO-207 guides accelerated path; blinded PK data from ALTO-100 and ALTO-101 showed 96% and 100% compliance.","Terminated $75M Sales Agreement with Leerink Partners; no shares sold under it.","Cash runway extended into 2028 including additional ALTO-207 activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-100801","json":"https://secwatch.observer/filing/0001104659-25-100801.json","markdown":"https://secwatch.observer/filing/0001104659-25-100801.md","text":"https://secwatch.observer/filing/0001104659-25-100801.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000110465925100801/0001104659-25-100801-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000110465925100801/tm2529007d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:18:36.739279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}